Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012

Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012 14.1 KB

RDX5791, A NON-SYSTEMIC NHE3 INHIBITOR, ALONE OR IN COMBINATION WITH ENALAPRIL, PREVENTS CARDIOVASCULAR AND RENAL DYSFUNCTION IN SALT FED RATS WITH RENAL INSUFFICIENCY

Andrew G. Spencer1, Marc Navre1, Craig F. Plato2, Kristin M. Joly2, Kevin Ida2, Eric D. Labonte1, Jeffrey W. Jacobs1 and Dominique Charmot1.

1- Ardelyx, Inc., Fremont, CA, United States and

2 -Plato BioPharma, Inc., Westminster, CO, United States

FAQs

Email Alerts

Connect

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Milwaukee
260 East Highland Avenue
Milwaukee, WI 53202

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com

Press Release Details

Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012